Didier has 25 years’ experience in drug delivery using colloids, ranging from basic research to clinical studies. As an international expert in nanomedicine, he presided at the French Society for Controlled Release, was a board member of the French Society of Nanomedicine, and has over 80 international publications and 23 patents.
After a PhD on drug targeting in collaboration with the World Health Organization, Didier developed a patented technology for vaccine applications based on polysaccharidic nanoparticles with a phospholipid bi-layer. This technology has since been used in both research and clinical trials, notably for influenza vaccine formulations (BioChem Pharma, Canada). He has also worked internationally on clinical trials with SmithKline Beecham and Chiron, and has collaborated with RIBI Immunochem, Merck and Sanofi Pasteur.
His experience, innovative research and patented technology are at the heart of Vaxinano.
Boris has a strong experience as business and licensing director, specialized in pharmaceutic and in medical devices. He supported the technology transfer of academic research by the creation of 13 start-ups and the signing of more than 35 license agreements.
Holding a PhD in physics with the CEA of Grenoble, France, consolidated by a post-doctoral position in the University of Twente in the Netherlands, he was project manager and scientist in UK and Belgium (Imperial chemical industries, Flamac, Umicore, Agfa). He then engaged this international R&D experience into Biotech Company and start-up development, managing the IP, the licensing and patent strategy, the technology transfer and the business model for 10 years.
With this dual expertise in science and business, he joined Vaxinano as Chief Operating Officer.
